Collaboration AGREEMENTCollaboration Agreement • March 24th, 2016 • Checkpoint Therapeutics, Inc. • Pharmaceutical preparations • New York
THIS COLLABORATION AGREEMENT (the “Agreement”) is dated as of March 3, 2015 (the “Effective Date”) by and between Checkpoint Therapeutics, Inc., a Delaware corporation organized having its place of business at 3 Columbus Circle, New York, NY 10019 (“CTI”), and TG Therapeutics, Inc. located at 3 Columbus Circle, New York, NY 10019 (“TGTX”). CTI, on the one hand, and TGTX, on the other hand, shall each be referred to herein as a “Party” or, collectively, as the “Parties.”
MANAGEMENT SERVICES AGREEMENTManagement Services Agreement • March 24th, 2016 • Checkpoint Therapeutics, Inc. • Pharmaceutical preparations • New York
THIS MANAGEMENT SERVICES AGREEMENT (this “Agreement”) is made as of March 17, 2015, by and between Checkpoint Therapeutics, Inc. a Delaware corporation (the “Company”), and Fortress Biotech, Inc., a Delaware corporation (the “Manager” and individually a “Party” or collectively the “Parties”).
FOUNDERS AGREEMENTFounders Agreement • March 24th, 2016 • Checkpoint Therapeutics, Inc. • Pharmaceutical preparations • New York
THIS FOUNDERS AGREEMENT (this “Agreement”) is entered into as of March 17, 2015 (the “Effective Date”) by and between Fortress Biotech, Inc., a Delaware corporation (the “Founder”), and Checkpoint Therapeutics, Inc. (the “Company”).
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • March 24th, 2016 • Checkpoint Therapeutics, Inc. • Pharmaceutical preparations • New York
This Executive Employment Agreement (this “Agreement”) is made and entered into as of October 13, 2015 by and between Checkpoint Therapeutics, Inc. (the “Company”) and James F. Oliviero III (“Executive”). The Company and Executive are hereinafter collectively referred to as the “Parties”, and individually referred to as a “Party”.
CONFIDENTIAL LICENSE AGREEMENTLicense Agreement • March 24th, 2016 • Checkpoint Therapeutics, Inc. • Pharmaceutical preparations • New York
THIS LICENSE AGREEMENT (the “Agreement”) is dated as of March 17, 2015 (the “Effective Date”) by and between NeuPharma, Inc., a Delaware corporation having its place of business at 1175 Chess Dr, Ste 206, Foster City, CA 94404 (“Licensor”), and Coronado Biosciences, Inc., a Delaware corporation with its place of business at 3 Columbus Circle, 15th Floor, New York, New York 10019 (“Coronado”). Coronado, on the one hand, and Licensor, on the other hand, shall each be referred to herein as a “Party” or, collectively, as the “Parties.”
LICENSE AGREEMENTLicense Agreement • March 24th, 2016 • Checkpoint Therapeutics, Inc. • Pharmaceutical preparations • New York
THIS LICENSE AGREEMENT (the “Agreement”) is dated as of March 2, 2015 (the “Effective Date”) by and between Checkpoint Therapeutics, Inc., a Delaware corporation organized having its place of business at 3 Columbus Circle, New York, NY 10019 (“CTI”), and Dana-Farber Cancer Institute, Inc. located at 450 Brookline Ave., Boston, MA 02115 (“DFCI”). CTI, on the one hand, and DFCI, on the other hand, shall each be referred to herein as a “Party” or, collectively, as the “Parties.”
LICENSE AGREEMENT FOR CEP-9722License Agreement • March 24th, 2016 • Checkpoint Therapeutics, Inc. • Pharmaceutical preparations • New York
THIS LICENSE AGREEMENT (this “Agreement”) is dated as of December 18, 2015 (the “Effective Date”) by and between Fortress Biotech, Inc., a Delaware corporation organized having its place of business at 3 Columbus Circle, New York, NY 10019 (“FBIO”), and Cephalon, Inc. a Delaware corporation having its place of business at 41 Moores Road, Frazier, PA 19355 (“Cephalon”). FBIO, on the one hand, and Cephalon, on the other hand, shall each be referred to herein as a “Party” or, collectively, as the “Parties.”
Amendment 1 to Exclusive License Agreement between Checkpoint Therapeutics, Inc. and Dana-Farber Cancer Institute, Inc.Confidential Treatment • March 24th, 2016 • Checkpoint Therapeutics, Inc. • Pharmaceutical preparations
This first amendment (“Amendment 1”), made effective as of October 5, 2015 (“Amendment 1 Effective Date”), is between the Dana-Farber Cancer Institute, Inc., a Massachusetts non-profit organization having offices at 450 Brookline Avenue, Boston, MA 02215 (“DFCI”), and Checkpoint Therapeutics, Inc., a Delaware corporation with offices at 3 Columbus Circle, New York, NY 10019 (“CTI”), collectively the “Parties” with reference to the following:
